The first patient has been dosed in a phase 1 dose-finding clinical trial evaluating iadademstat with Vidaza in patients with ...

The Global Stem Cell Factor (SCF) Market was valued at USD 12900 Million in 2023 and is anticipated to reach USD Million by ...

Aptose Biosciences (NASDAQ:APTO), a biotechnology company specializing in novel therapeutics to treat life-threatening diseases, including cancer, operates out of Toronto, Canada. The company's focus ...